EMEA-002784-PIP01-20 - paediatric investigation plan

fruquintinib

Key facts

• Active Substance:
  fruquintinib
• Therapeutic area:
  Oncology
• Decision number:
  P/0360/2020
• PIP number:
  EMEA-002784-PIP01-20
• Pharmaceutical form(s):
  Capsule (hard)
• Condition(s) / indication(s):
  Treatment of colorectal carcinoma
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Hutchison MediPharma Ltd

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  09/09/2020

Decision

P/0360/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for fruquintinib (EMEA-002784-PIP01-20)

AdoptedReference Number: EMA/432675/2020